210 related articles for article (PubMed ID: 36002192)
1. [Chinese Expert Consensus on Management of Special Adverse Effects
Associated with Lorlatinib].
Zhou Q; Lu S; Li Y; Jia F; Li G; Hong Z; Lu Y; Fan Y; Zhou J; Liu Z; Li J; Wu YL; ;
Zhongguo Fei Ai Za Zhi; 2022 Aug; 25(8):555-566. PubMed ID: 36002192
[TBL] [Abstract][Full Text] [Related]
2. Clinical Management of Adverse Events Associated with Lorlatinib.
Bauer TM; Felip E; Solomon BJ; Thurm H; Peltz G; Chioda MD; Shaw AT
Oncologist; 2019 Aug; 24(8):1103-1110. PubMed ID: 30890623
[TBL] [Abstract][Full Text] [Related]
3.
Shaw AT; Solomon BJ; Besse B; Bauer TM; Lin CC; Soo RA; Riely GJ; Ou SI; Clancy JS; Li S; Abbattista A; Thurm H; Satouchi M; Camidge DR; Kao S; Chiari R; Gadgeel SM; Felip E; Martini JF
J Clin Oncol; 2019 Jun; 37(16):1370-1379. PubMed ID: 30892989
[TBL] [Abstract][Full Text] [Related]
4. Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study.
Seto T; Hayashi H; Satouchi M; Goto Y; Niho S; Nogami N; Hida T; Takahashi T; Sakakibara-Konishi J; Morise M; Nagasawa T; Suzuki M; Ohkura M; Fukuhara K; Thurm H; Peltz G; Nishio M
Cancer Sci; 2020 Oct; 111(10):3726-3738. PubMed ID: 32681682
[TBL] [Abstract][Full Text] [Related]
5. Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort.
Baldacci S; Besse B; Avrillon V; Mennecier B; Mazieres J; Dubray-Longeras P; Cortot AB; Descourt R; Doubre H; Quantin X; Duruisseaux M; Monnet I; Moro-Sibilot D; Cadranel J; Clément-Duchêne C; Cousin S; Ricordel C; Merle P; Otto J; Schneider S; Langlais A; Morin F; Westeel V; Girard N
Eur J Cancer; 2022 May; 166():51-59. PubMed ID: 35278825
[TBL] [Abstract][Full Text] [Related]
6. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Shaw AT; Felip E; Bauer TM; Besse B; Navarro A; Postel-Vinay S; Gainor JF; Johnson M; Dietrich J; James LP; Clancy JS; Chen J; Martini JF; Abbattista A; Solomon BJ
Lancet Oncol; 2017 Dec; 18(12):1590-1599. PubMed ID: 29074098
[TBL] [Abstract][Full Text] [Related]
7. Consensus Recommendations for Management and Counseling of Adverse Events Associated With Lorlatinib: A Guide for Healthcare Practitioners.
Reed M; Rosales AS; Chioda MD; Parker L; Devgan G; Kettle J
Adv Ther; 2020 Jun; 37(6):3019-3030. PubMed ID: 32399810
[TBL] [Abstract][Full Text] [Related]
8. Establishment of an acquired lorlatinib-resistant cell line of non-small cell lung cancer and its mediated resistance mechanism.
Xie B; Qiu Y; Zhou J; Du D; Ma H; Ji J; Zhu L; Zhang W
Clin Transl Oncol; 2022 Nov; 24(11):2231-2240. PubMed ID: 35852680
[TBL] [Abstract][Full Text] [Related]
9. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT
Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
[TBL] [Abstract][Full Text] [Related]
10. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
Lin YT; Chiang CL; Hung JY; Lee MH; Su WC; Wu SY; Wei YF; Lee KY; Tseng YH; Su J; Chung HP; Lin CB; Ku WH; Chiang TS; Chiu CH; Shih JY
Eur J Cancer; 2021 Oct; 156():1-11. PubMed ID: 34392186
[TBL] [Abstract][Full Text] [Related]
11. Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy.
Jóri B; Falk M; Hövel I; Weist P; Tiemann M; Heukamp LC; Griesinger F
Curr Oncol; 2022 Sep; 29(9):6628-6634. PubMed ID: 36135089
[TBL] [Abstract][Full Text] [Related]
12. A pragmatic guide for management of adverse events associated with lorlatinib.
Liu G; Mazieres J; Stratmann J; Ou SI; Mok T; Grizzard M; Goto Y; Felip E; Solomon BJ; Bauer TM
Lung Cancer; 2024 May; 191():107535. PubMed ID: 38554546
[TBL] [Abstract][Full Text] [Related]
13. Lorlatinib for the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer.
Yang J; Gong W
Expert Rev Clin Pharmacol; 2019 Mar; 12(3):173-178. PubMed ID: 30657349
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological and clinical properties of lorlatinib in the treatment of
El Darsa H; Abdel-Rahman O; Sangha R
Expert Opin Pharmacother; 2020 Sep; 21(13):1547-1554. PubMed ID: 32511029
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial.
Soo RA; Huat Tan E; Hayashi H; Seto T; Lin CC; Ou SI; Kim DW; Liu G; Abbattista A; Martini JF; Hooi Wong C; Toffalorio F; Solomon BJ
Lung Cancer; 2022 Jul; 169():67-76. PubMed ID: 35660971
[TBL] [Abstract][Full Text] [Related]
16. Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer.
Bauer TM; Shaw AT; Johnson ML; Navarro A; Gainor JF; Thurm H; Pithavala YK; Abbattista A; Peltz G; Felip E
Target Oncol; 2020 Feb; 15(1):55-65. PubMed ID: 32060867
[TBL] [Abstract][Full Text] [Related]
17. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L
Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242
[TBL] [Abstract][Full Text] [Related]
18. LTK mutations responsible for resistance to lorlatinib in non-small cell lung cancer harboring CLIP1-LTK fusion.
Mori S; Izumi H; Araki M; Liu J; Tanaka Y; Kagawa Y; Sagae Y; Ma B; Isaka Y; Sasakura Y; Kumagai S; Sakae Y; Tanaka K; Shibata Y; Udagawa H; Matsumoto S; Yoh K; Okuno Y; Goto K; Kobayashi SS
Commun Biol; 2024 Apr; 7(1):412. PubMed ID: 38575808
[TBL] [Abstract][Full Text] [Related]
19. Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases.
Naito T; Shiraishi H; Fujiwara Y
Jpn J Clin Oncol; 2021 Jan; 51(1):37-44. PubMed ID: 33147606
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Lorlatinib Cerebrospinal Fluid Concentrations in Relation to Target Concentrations for Anaplastic Lymphoma Kinase (ALK) Inhibition.
Sun S; Pithavala YK; Martini JF; Chen J
J Clin Pharmacol; 2022 Sep; 62(9):1170-1176. PubMed ID: 35373356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]